Ginkgo Bioworks Holdings, Inc. (DNA) 8-K Current Report — February 26, 2026
Filed: February 26, 2026
Health Care
Biological Products, (No Diagnostic Substances)Ginkgo Bioworks Holdings, Inc. (DNA) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
Ginkgo Bioworks Holdings, Inc. 8-K Feb 26, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 2025 and full-year results ending Dec 31, 2025 announced Feb 26, 2026
- • Actual figures in Exhibit 99.1 — key metrics (revenue, margins, cash position) require reviewing attached press release
Other Ginkgo Bioworks Holdings, Inc. 8-K Filings
Get deeper insights on Ginkgo Bioworks Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.